The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats

Journal of Psychopharmacology

Volumn 27, Issue 5, 2013, Pages 469-476

  Nikiforuk, Agnieszka ^a   Fijał, Katarzyna ^a   Potasiewicz, Agnieszka ^a   Popik, Piotr ^a   Kos, Tomasz ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT6 receptor agonist; animal models; Cognition; ketamine; NMDA receptor; novel object recognition; prepulse inhibition; schizophrenia; set shifting

Indexed keywords

CLOZAPINE; EMD 386088; KETAMINE; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTIONAL SET SHIFTING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MENTAL TASK; NONHUMAN; NOVEL OBJECT RECOGNITION; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; CLOZAPINE; COGNITION DISORDERS; INDOLES; KETAMINE; MALE; PATTERN RECOGNITION, PHYSIOLOGICAL; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN RECEPTOR AGONISTS;

EID: 84876577674     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113480991     Document Type: Article

References (41)

1. Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 ; 13: 1021-1033
2. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 1994 ; 271: 787-794
3. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci. 2000 ; 20: 4320-4324
4. Bonasera SJ, Chu HM, Brennan TJ, et al. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology. 2006 ; 31: 1801-1813
5. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 1992 ; 49: 206-215
6. Burnham KE, Baxter MG, Bainton JR, et al. Activation of 5-HT(6) receptors facilitates attentional set shifting. Psychopharmacology (Berl). 2010 ; 208: 13-21
7. Calkins ME, Gur RC, Ragland JD, et al. Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. Am J Psychiatry. 2005 ; 162: 1963-1966
8. Carr GV, Schechter LE, Lucki I. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology (Berl). 2011 ; 213: 499-507
9. Cilia J, Hatcher P, Reavill C, et al. (+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol. 2007 ; 21: 302-311
10. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000 ; 14: 1-21
11. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988 ; 31: 47-59
12. Floresco SB, Zhang Y, Enomoto T. Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res. 2009 ; 204: 396-409
13. Fone KC. An update on the role of the 5-hydroxytryptamine 6 receptor in cognitive function. Neuropharmacology. 2008 ; 55: 1015-1022
14. Gravius A, Laszy J, Pietraszek M, et al. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol. 2011 ; 22: 122-135
15. Heal DJ, Smith SL, Fisas A, et al. Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008 ; 117: 207-231
16. Idris N, Neill J, Grayson B, et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: Involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl). 2010 ; 208: 23-36
17. Kendall I, Slotten HA, Codony X, et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl). 2011 ; 213: 413-430
18. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994 ; 51: 199-214
19. Leng A, Ouagazzal A, Feldon J, et al. Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: Comparison to clozapine. Pharmacol Biochem Behav. 2003 ; 75: 281-288
20. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008 ; 31: 234-242
21. Loiseau F, Dekeyne A, Millan MJ. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: Implication of the frontal cortex. Psychopharmacology (Berl). 2008 ; 196: 93-104
22. Mattsson C, Sonesson C, Sandahl A, et al. 2-Alkyl-3-(1,2,3,6- tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 ; 15: 4230-4234
23. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl). 2011 ; 213: 289-305
24. Meneses A, Perez-Garcia G, Liy-Salmeron G, et al. The effects of the 5-HT(6) receptor agonist EMD and the 5-HT(7) receptor agonist AS19 on memory formation. Behav Brain Res. 2008 ; 195: 112-119
25. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998 ; 281: 1349-1352
26. Morozova MA, Beniashvili AG, Lepilkina TA, et al. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012 ; 24: 159-166
27. Nikiforuk A, Popik P. Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology (Berl). 2012 ; 220: 65-74
28. Nikiforuk A, Golembiowska K, Popik P. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol. 2010 ; 20: 37-48
29. Pitsikas N, Boultadakis A, Sakellaridis N. Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory. Neuroscience. 2008 ; 154: 454-460
30. Pouzet B, Didriksen M, Arnt J. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav. 2002 ; 71: 635-643
31. Rodefer JS, Nguyen TN, Karlsson JJ, et al. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: Comparison among antipsychotics. Neuropsychopharmacology. 2008 ; 33: 2657-2666
32. Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology. 2008 ; 33: 1323-1335
33. Svenningsson P, Tzavara ET, Qi H, et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci. 2007 ; 27: 4201-4209
34. Swerdlow NR, Bakshi V, Waikar M, et al. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl). 1998 ; 140: 75-80
35. Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: What we know, what we think we know, and what we hope to know soon. Behav Pharmacol. 2000 ; 11: 185-204
36. Tassone A, Madeo G, Schirinzi T, et al. Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology. 2011 ; 61: 632-637
37. Valentini V, Frau R, Bordi F, et al. A microdialysis study of ST1936, a novel 5-HT6 receptor agonist. Neuropharmacology. 2011 ; 60: 602-608
38. Wesolowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 2007 ; 52: 1274-1283
39. Woods S, Clarke N, Layfield R, et al. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br J Pharmacol. 2012 ; 167: 436-449
40. Woolley ML, Marsden CA, Fone KC. 5-HT6 receptors. Curr Drug Targets CNS Neurol Disord. 2004 ; 3: 59-79
41. Yun HM, Kim S, Kim HJ, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem. 2007 ; 282: 5496-5505